Octave Specialty Group (OSG)
NYSE:OSG
Top Page
Octave Specialty Group
(NYSE:OSG)
Select Model
Select Model
Rating:49Neutral
Price Target:
$5.00
▼(-3.85% Downside)
Action:ReiteratedDate:03/24/26
The score is held back primarily by weak financial performance (large losses and renewed 2025 cash burn) and bearish technical trends. Offsetting this somewhat is constructive earnings-call guidance with identifiable growth, margin, and cost-reduction targets, though valuation support is limited due to negative earnings.
Positive Factors
Rapid top-line expansion
Sustained, large revenue growth in 2025 demonstrates the company is scaling core businesses (Insurance Distribution and Ventures). Durable top-line expansion increases potential for operating leverage, supports investment in MGAs and technology, and underpins long-term margin improvement if growth converts to profitable scale.
Negative Factors
Persistent large net losses
Continued multi-year net losses erode returns and constrain reinvestment from internal funds. Large negative margins imply that until adjusted profitability converts to reported profitability, shareholder returns and retained earnings will lag expectations and external financing or equity dilution may be needed to fund growth or cover impairments.
Read all positive and negative factors
Positive Factors
Negative Factors
Rapid top-line expansion
Sustained, large revenue growth in 2025 demonstrates the company is scaling core businesses (Insurance Distribution and Ventures). Durable top-line expansion increases potential for operating leverage, supports investment in MGAs and technology, and underpins long-term margin improvement if growth converts to profitable scale.
Read all positive factors
Octave Specialty Group (OSG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$209.48M
Dividend YieldN/A
Average Volume (3M)749.19K
Price to Earnings (P/E)―
Beta (1Y)0.94
Revenue Growth-37.46%
EPS Growth-117.36%
CountryUS
Employees380
SectorFinancial
Sector Strength70
IndustryInsurance - Specialty
Share Statistics
EPS (TTM)-0.02
Shares Outstanding44,951,912
10 Day Avg. Volume528,569
30 Day Avg. Volume749,192
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.51
Price to Sales (P/S)1.46
P/FCF Ratio-7.02
Enterprise Value/Market Cap1.29
Enterprise Value/Revenue1.08
Enterprise Value/Gross Profit1.33
Enterprise Value/Ebitda-6.70
Forecast
1Y Price Target
$15.00Price Target Upside188.46% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.33
Revenue Forecast (FY)$69.79M
Octave Specialty Group Business Overview & Revenue Model
Company Description
Octave Specialty Group, Inc. operates as a financial services holding company. It operates in two segments, Specialty Property and Casualty Insurance; and Insurance Distribution. The Specialty Property and Casualty Insurance segment provides speci...
Octave Specialty Group Earnings Call Summary
Earnings Call Date:Feb 23, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:May 11, 2026
Earnings Call Sentiment Positive
The call presented a constructive growth story driven by a rapidly scaling Insurance Distribution platform, strong organic and Ventures revenue growth, margin improvement in distribution, accretive high-margin acquisition (ArmadaCare), AI/tech differentiation, and clear 2026 guidance. These positives were offset by transitional reported losses driven by acquisition and one-time corporate costs, impairments, start-up investment drag, and near-term pressure in some P&C pricing areas. Management framed the negatives as largely transactional and part of a multi-year scaling strategy, with several metrics (adjusted EBITDA, distribution margins, Ventures growth, combined ratio) trending favorably toward management targets.Positive Updates
Strong Insurance Distribution Revenue Growth
Insurance Distribution business revenue grew 65% over 2024, including 14% organic growth (note: excludes 8 months of Octave Ventures and ArmadaCare acquisition).
Negative Updates
Reported Net Loss and Per-Share Decline
Q4 2025 net loss to shareholders of $30M ($0.84 per share) versus a net loss of $22M ($0.56 per share) in Q4 2024, driven by acquisition costs, exit from the financial guarantee business, restructuring and an impairment.
Read all updates
Q4-2025 Updates
Positive
Negative
Strong Insurance Distribution Revenue Growth
Insurance Distribution business revenue grew 65% over 2024, including 14% organic growth (note: excludes 8 months of Octave Ventures and ArmadaCare acquisition).
Read all positive updates
Company Guidance
Octave guided to tangible 2026 targets: Insurance Distribution is expected to deliver at least 20% organic revenue growth and roughly $40 million of adjusted EBITDA (with segment margins trending toward mid-20s over time; Q4 '25 adj. EBITDA margin was 15% and operating basis 22.6%), Specialty Insurance (including Everspan) is projected to write about $410 million of gross written premiums and produce approximately $7.5 million of adjusted EBITDA, corporate adjusted expenses are expected to be below $30 million, and consolidated adjusted net income is targeted at about $0.50 per share; management also said NCI buy-ins this year should be less than $50 million (to be funded from cash and modest incremental borrowing), net investment income should be flat to marginally higher, equity-based comp should be down a few million versus 2025, ArmadaCare contributes >40% EBITDA margins and A&H earnings are seasonally weighted (about 60% in Q1), and corporate expense-reduction initiatives are estimated to yield roughly $17 million of reported savings (and >$10 million benefit to adjusted corporate EBITDA) when fully realized.Octave Specialty Group Financial Statement Overview
Summary
Income Statement
36
Negative
Balance Sheet
62
Positive
Cash Flow
41
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 251.22M | 235.81M | 124.73M | 53.61M | 247.00M |
| Gross Profit | 204.03M | 98.65M | 47.99M | 24.36M | 319.00M |
| EBITDA | -40.42M | -30.52M | -18.99M | -31.91M | 246.00M |
| Net Income | -240.92M | -556.45M | 3.63M | 521.25M | -17.00M |
Balance Sheet | |||||
| Total Assets | 2.22B | 8.06B | 8.43B | 7.97B | 12.30B |
| Cash, Cash Equivalents and Short-Term Investments | 68.44M | 331.90M | 354.96M | 1.93B | 1.85B |
| Total Debt | 127.41M | 150.00M | 3.48B | 3.75B | 6.45B |
| Total Liabilities | 1.14B | 6.86B | 7.00B | 6.65B | 11.19B |
| Stockholders Equity | 715.79M | 856.91M | 1.36B | 1.25B | 1.04B |
Cash Flow | |||||
| Free Cash Flow | -52.28M | 762.00K | 200.00M | 70.37M | -131.00M |
| Operating Cash Flow | -52.28M | 762.00K | 200.00M | 70.37M | -131.00M |
| Investing Cash Flow | 198.23M | -166.37M | 435.00M | -41.16M | 776.00M |
| Financing Cash Flow | -126.30M | 194.22M | -423.00M | -19.23M | -657.00M |
Octave Specialty Group Technical Analysis
5.20
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSG, the sentiment is undefined. The current price of 5.2 is equal to the 20-day moving average (MA) of ―, equal to the 50-day MA of ―, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a undefined sentiment for OSG.
Octave Specialty Group Peers Comparison
UnderperformOutperform
Sector (68)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $18.00B | 11.42 | 9.92% | 3.81% | 9.73% | 1.22% |
* Financial Sector Average
Performance Comparison
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.